Akero Therapeutics, Inc. (NASDAQ:AKRO) Insider Sells $1,376,000.00 in Stock

Akero Therapeutics, Inc. (NASDAQ:AKRO - Get Free Report) insider Timothy Rolph sold 25,000 shares of Akero Therapeutics stock in a transaction that occurred on Friday, June 6th. The stock was sold at an average price of $55.04, for a total value of $1,376,000.00. Following the sale, the insider now owns 169,721 shares in the company, valued at $9,341,443.84. This represents a 12.84% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Timothy Rolph also recently made the following trade(s):

• On Tuesday, June 10th, Timothy Rolph sold 2,358 shares of Akero Therapeutics stock. The stock was sold at an average price of $54.00, for a total transaction of $127,332.00.
• On Thursday, June 5th, Timothy Rolph sold 12,500 shares of Akero Therapeutics stock. The stock was sold at an average price of $53.49, for a total transaction of $668,625.00.
• On Tuesday, May 6th, Timothy Rolph sold 12,500 shares of Akero Therapeutics stock. The stock was sold at an average price of $43.43, for a total transaction of $542,875.00.
• On Thursday, April 24th, Timothy Rolph sold 6,250 shares of Akero Therapeutics stock. The stock was sold at an average price of $41.03, for a total value of $256,437.50.
• On Monday, April 7th, Timothy Rolph sold 6,250 shares of Akero Therapeutics stock. The shares were sold at an average price of $35.88, for a total value of $224,250.00.

Akero Therapeutics Trading Up 1.1%

NASDAQ AKRO traded up $0.60 on Thursday, hitting $53.56. 1,573,450 shares of the stock were exchanged, compared to its average volume of 1,001,064. The company's 50-day moving average price is $43.18 and its two-hundred day moving average price is $39.98. The company has a debt-to-equity ratio of 0.05, a current ratio of 17.25 and a quick ratio of 17.25. Akero Therapeutics, Inc. has a 52-week low of $21.02 and a 52-week high of $58.40. The company has a market capitalization of $4.27 billion, a price-to-earnings ratio of -14.28 and a beta of -0.16.

Akero Therapeutics (NASDAQ:AKRO - Get Free Report) last posted its quarterly earnings results on Monday, May 12th. The company reported $0.90 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.01) by $1.91. Research analysts predict that Akero Therapeutics, Inc. will post -3.99 EPS for the current year.

Institutional Investors Weigh In On Akero Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the business. RTW Investments LP increased its holdings in shares of Akero Therapeutics by 15.9% during the 4th quarter. RTW Investments LP now owns 6,859,823 shares of the company's stock valued at $190,840,000 after acquiring an additional 940,388 shares during the last quarter. Deep Track Capital LP lifted its holdings in Akero Therapeutics by 116.0% in the 4th quarter. Deep Track Capital LP now owns 1,490,000 shares of the company's stock worth $41,452,000 after purchasing an additional 800,216 shares during the last quarter. Balyasny Asset Management L.P. acquired a new stake in Akero Therapeutics in the 4th quarter worth approximately $18,059,000. SG Americas Securities LLC boosted its position in Akero Therapeutics by 93.3% during the first quarter. SG Americas Securities LLC now owns 1,155,787 shares of the company's stock worth $46,786,000 after purchasing an additional 557,794 shares during the period. Finally, Lord Abbett & CO. LLC bought a new stake in Akero Therapeutics during the first quarter worth approximately $21,333,000.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the company. Citigroup reduced their price objective on Akero Therapeutics from $80.00 to $78.00 and set a "buy" rating on the stock in a research note on Tuesday, May 13th. Morgan Stanley reissued an "overweight" rating on shares of Akero Therapeutics in a report on Sunday, March 2nd. HC Wainwright lifted their price target on shares of Akero Therapeutics from $72.00 to $75.00 and gave the company a "buy" rating in a report on Monday, March 3rd. Finally, Bank of America boosted their price objective on shares of Akero Therapeutics from $63.00 to $64.00 and gave the company a "buy" rating in a research report on Tuesday, May 27th. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has an average rating of "Buy" and an average price target of $82.50.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.